AIM ImmunoTech (NYSEAMERICAN:AIM) Upgraded at Zacks Research

Zacks Research upgraded shares of AIM ImmunoTech (NYSEAMERICAN:AIM) from a hold rating to a strong-buy rating in a research note published on Tuesday,Zacks.com reports.

Separately, Maxim Group upgraded shares of AIM ImmunoTech to a “strong-buy” rating in a research report on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Strong Buy” and an average target price of $275.00.

AIM ImmunoTech Trading Down 1.5%

AIM ImmunoTech stock opened at $2.61 on Tuesday. AIM ImmunoTech has a 1-year low of $2.33 and a 1-year high of $36.00. The firm has a market capitalization of $7.07 million, a price-to-earnings ratio of -0.11 and a beta of 1.03. The firm has a 50 day simple moving average of $2.60 and a 200 day simple moving average of $6.62.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC bought a new position in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 1.31% of AIM ImmunoTech as of its most recent filing with the Securities & Exchange Commission. 12.02% of the stock is currently owned by hedge funds and other institutional investors.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).